English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Background  The purpose of the study was to evaluate the applicability of   18  F-labelled amyloid imaging positron emission tomography (PET) agent [  18  F]flutemetamol to detect changes in brain beta-amyloid (Aβ) deposition  in vivo  in APP23, Tg2576 and APPswe-PS1dE9 mouse models of Alzheimer's disease. We expected that the high specific activity of [  18  F]flutemetamol would make it an attractive small animal Aβ imaging agent.    Methods  [  18  F]flutemetamol uptake in the mouse brain was evaluated  in vivo  at 9 to 22 months of age with an Inveon Multimodality PET/CT camera (Siemens Medical Solutions USA, Knoxville, TN, USA). Retention in the frontal cortex (FC) was evaluated by Logan distribution volume ratios (DVR) and FC/cerebellum (CB) ratios during the late washout phase (50 to 60 min). [  18  F]flutemetamol binding to Aβ was also evaluated in brain slices by  in vitro  and  ex vivo  autoradiography. The amount of Aβ in the brain slices was determined with Thioflavin S and anti-Aβ 1−40  immunohistochemistry.    Results  In APP23 mice, [  18  F]flutemetamol retention in the FC increased from 9 to 18 months. In younger mice, DVR and FC/CB 50-60  were 0.88 (0.81) and 0.88 (0.89) at 9 months ( N  = 2), and 0.98 (0.93) at 12 months ( N  = 1), respectively. In older mice, DVR and FC/CB 50-60  were 1.16 (1.15) at 15 months ( N  = 1), 1.13 (1.16) and 1.35 (1.35) at 18 months ( N  = 2), and 1.05 (1.31) at 21 months ( N  = 1). In Tg2576 mice, DVR and FC/CB 50-60  showed modest increasing trends but also high variability. In APPswe-PS1dE9 mice, DVR and FC/CB 50-60  did not increase with age. Thioflavin S and anti-Aβ 1−40  positive Aβ deposits were present in all transgenic mice at 19 to 22 months, and they co-localized with [  18  F]flutemetamol binding in the brain slices examined with  in vitro  and  ex vivo  autoradiography .Conclusions  Increased [  18  F]flutemetamol retention in the brain was detected in old APP23 mice  in vivo . However, the high specific activity of [  18  F]flutemetamol did not provide a notable advantage in Tg2576 and APPswe-PS1dE9 mice compared to the previously evaluated structural analogue [ 11 C]PIB. For its practical benefits, [  18  F]flutemetamol imaging with a suitable mouse model like APP23 is an attractive alternative.

ejnmmi research

In vivo PET imaging of beta-amyloid deposition in mouse models of Alzheimer's disease with a high specific activity PET imaging agent [18F]flutemetamol